An experimental AI-designed "universal" coronavirus vaccine has successfully completed its Phase 1 human clinical trial, demonstrating a 100% safety profile with no serious adverse reactions among 39 adult volunteers, according to data published in the Journal of Infection. Developed by the University of Cambridge and DIOSynVax, this vaccine was created by AI scanning coronavirus genetic sequences to identify common features and design a synthetic "super-antigen," offering a proactive approach against mutating viruses, unlike traditional reactive vaccines. While this specific coronavirus vaccine does not cross-protect against Ebola, the same AI platform is now being utilized to develop a universal Ebola vaccine, aiming to address the limitations of existing vaccines that are only effective against specific strains, especially in light of recent Ebola outbreaks like the Bundibugyo strain in the Democratic Republic of Congo.

An experimental AI-designed "universal" coronavirus vaccine has successfully completed its Phase 1 human clinical trial, demonstrating a 100% safety profile with no serious adverse reactions among 39 adult volunteers, according to data published in the Journal of Infection. Developed by the University of Cambridge and DIOSynVax, this vaccine was created by AI scanning coronavirus genetic sequences to identify common features and design a synthetic "super-antigen," offering a proactive approach against mutating viruses, unlike traditional reactive vaccines. While this specific coronavirus vaccine does not cross-protect against Ebola, the same AI platform is now being utilized to develop a universal Ebola vaccine, aiming to address the limitations of existing vaccines that are only effective against specific strains, especially in light of recent Ebola outbreaks like the Bundibugyo strain in the Democratic Republic of Congo.

An experimental AI-designed "universal" coronavirus vaccine has successfully completed its Phase 1 human clinical trial, demonstrating a 100% safety profile with no serious adverse reactions among 39 adult volunteers, according to data published in the Journal of Infection. Developed by the University of Cambridge and DIOSynVax, this vaccine was created by AI scanning coronavirus genetic sequences to identify common features and design a synthetic "super-antigen," offering a proactive approach against mutating viruses, unlike traditional reactive vaccines. While this specific coronavirus vaccine does not cross-protect against Ebola, the same AI platform is now being utilized to develop a universal Ebola vaccine, aiming to address the limitations of existing vaccines that are only effective against specific strains, especially in light of recent Ebola outbreaks like the Bundibugyo strain in the Democratic Republic of Congo.

In a breakthrough, an experimental "universal" coronavirus vaccine designed entirely by artificial intelligence (AI) has successfully completed its first human clinical trial. 

According to data published in the Journal of Infection, the Phase 1 clinical trial evaluated 39 healthy adult volunteers aged 18 to 50 and demonstrated a 100 pc safety profile. It also noted that none of the volunteers had any serious reactions to the vaccine. 

The vaccine developed by the research team at the University of Cambridge and the company DIOSynVax was claimed to elicit strong immune responses against various coronavirus strains effectively. 

This breakthrough achievement could pave the way for a universal Ebola vaccine, offering a proactive shield against a disease that continues to pose a significant global public health risk. 

How can the vaccine become successful against mutating viruses? 

Traditional vaccines are reactive, which means scientists look at a specific circulating strain and build a vaccine to match it. Therefore, they fall behind when the virus mutates.

By using machine learning to scan the genetic sequences of an entire family of coronaviruses. The AI identified the core features common to all of them—including strains that haven't even crossed over to humans yet—and computationally designed a synthetic "super-antigen". 

Though the coronavirus vaccine won't cross-protect against Ebola, researchers are now using the exact same computer-modelling platform to target the Ebola virus group. 

The existing WHO-recommended Ebola vaccines are highly effective against specific strains (like the Zaire strain), but they fail to protect the population from other variants, including Bundibugyo or Sudan strains. 

By feeding the genetic data of all known Ebola strains into the same AI platform, researchers are working to design a universal Ebola super-antigen. 

At least 452 confirmed cases and 82 deaths have been reported so far in the Democratic Republic of Congo due to the recent outbreak of the Bundibugyo strain of Ebola. 

TAGS